ReviewJournal for immunotherapy of cancer2026
Mapping the TCR landscape: computational tools empowering translational immunology and therapy design.
Review in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
T cell receptors (TCRs) are central to adaptive immunity, yet their vast sequence and structural diversity present a significant challenge to fully understand immune responses. The application of high-throughput sequencing technologies, including bulk and single-cell approaches, generates vast datasets of TCR repertoire information, requiring advanced computational tools for meaningful analysis. Here, we provide a comprehensive overview of the state-of-the-art in silico tools developed to enable diverse TCR repertoire analyses. We categorize over 40 computational tools into six primary analytical stages creating a workflow for TCR analysis in the context of cancer immunotherapy: (1) data acquisition, including differences between TCR sequencing technologies and databases; (2) TCR reconstruction and inference, which focuses on accurately extracting from raw sequencing data the V(D)J gene usage, including complementarity-determining region sequences, and the α/β pairing; (3) TCR clustering, which groups receptors based on similarity, helping characterize repertoire shifts, therapy responses and identify cancer-associated TCR clones; (4) structural modeling of TCRs and TCR-peptide-major histocompatibility complex (MHC), which is used to predict the three-dimensional structures of TCRs with or without their targets; (5) TCR specificity prediction, which predicts whether a given TCR can bind to a given peptide-MHC complex; and finally (6) functional and clinical integration, addressing the breakthroughs and bottlenecks for wider clinical application of these methods. For each category, we discuss the underlying methodologies, representative tools and their key applications, details about usability and accessibility, and comments on their strengths and limitations. With this overview, we offer a critical perspective on the current state of the field, providing an overall framework and guidance for new users and developers of these technologies. We also highlight open challenges and key future directions, particularly regarding the integration of multi-omics data and next-generation artificial intelligence approaches to unlock the full potential of TCR repertoire analysis for clinical immunotherapy applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.